Antitrust litigation against Dr Reddy’s Laboratories, Celgene and Bristol-Myers Squibb in US
The complaint has asked for equitable redress and damages for alleged over payments
An antitrust lawsuit was filed in the US against a number of generic pharmaceutical companies, including Dr Reddy’s Laboratories, Celgene, and Bristol-Myers Squibb.
Dr Reddy’s Laboratories reported in a regulatory filing that it and other generic pharmaceutical companies have been identified as defendants in a complaint that was filed on November 18, 2022, in the District of New Jersey, USA.
According to Dr Reddy’s Laboratories, the complaint asserts claims under federal and state antitrust laws as well as other state laws, alleging that the defendants improperly restricted competition and maintained a shared monopoly in the sale of brand-name and generic Revlimid through their respective settlements of patent litigation.
When combined with dexamethasone, the prescription drug Revlimid is used to treat adults with multiple myeloma (MM), or it can be used as a maintenance therapy after a particular type of stem cell transplant that employs the patient’s stem cells.
The case “alleges that the challenged agreements unfairly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026,” the firm said in a statement.
The complaint also asks for equitable redress and damages for alleged over payments.
Dr Reddy’s stated that it “would firmly defend the litigation” and that “the claims against it lack validity.”
PTI
